Used in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dysregulation of dopamine signaling. It modulates intracellular cAMP and cGMP levels in brain regions associated with cognition and behavior, making it a valuable tool compound in neuropharmacology studies. Its high blood-brain barrier permeability and favorable metabolic stability support its use in preclinical models to explore PDE10A's role in disease pathways.